首页> 外文OA文献 >Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs

【2h】

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs

机译：卓越的免疫疗法组合对单药治疗的优越疗效，对EGFR - 富小细胞肺癌获得抗EGFR-TKIS的抗性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lu Yang; Xuezhi Hao; Xingsheng Hu; Zhijie Wang; Ke Yang; Yuling Mi; Yaning Yang; Haiyan Xu; Guangjian Yang; Yan Wang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs [J] . Lu Yang, Xuezhi Hao, Xingsheng Hu, Thoracic cancer. . 2020,第12期

机译：卓越的免疫疗法组合对单药治疗的优越疗效，对EGFR-突变体非小细胞肺癌获得抗EGFR-TKIS的抗性
2. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell?lung?cancer: a propensity-matched retrospective study [J] . Wang Xia, Zeng Zhimin, Cai Jing, BMC Cancer . 2021,第1期

机译：EGFR-TKI Plus胸腔SBRT在高级Egfr-突变体非小细胞患者中的疗效和获得性抗性？肺部瘤：癌症：一种竞争匹配的回顾研究
3. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population [J] . Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2020,第期

机译：EGFR-TKI Plus Bevacizumab患有疗效和获得性抗性的疗效和抗emfr敏感突变体非小细胞肺癌患者的初级治疗
4. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA [C] . Cloud P. Paweletz, Geoffrey R. Oxnard, Yanan Kuang, Molecular Medicine TRI-CON. . 2014

机译：无细胞血浆DNA定量下一代基因分型非富集突变体肺癌响应和抗性的非侵袭性检测
5. The Effectiveness of EGFR-TKIs in Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis. [D] . Li, Xiao. 2016

机译：EGFR-TKIs在非小细胞肺癌治疗中的有效性：一项荟萃分析。
6. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study [O] . Xia Wang, Zhimin Zeng, Jing Cai, 2021

机译：EGFR-TKI加上胸腔SBRT在高级EGFR-突变体非小细胞肺癌患者中的疗效和获得性抗性：促进匹配的回顾性研究
7. Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study) [O] . M. Tamiya, A. Hata, N. Katakami, 2017

机译：AFATINIB（AFA）加上贝伐单抗（BEV）组合在收购抗原（AR）到EGFR-突变体非小细胞肺癌（NSCLC）中的EGFR-酪氨酸激酶抑制剂（TKIS）：多中心单臂第二次审判（ABC-SCOULE）
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR Mutant and ALK Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2016

机译：缺乏BIm表达作为EGFR突变体和aLK阳性肺癌中靶向治疗的内在和获得性抗性的机制。

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs

著录项

引文网络

相似文献

相关主题

期刊订阅